Medication-related osteonecrosis of the jaw: evolving research for multimodality medical management

[1] Ruggiero SL(2014)American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update J Oral Maxillofac Surg 72 1938-1956

[2] Yarom N(2019)Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO Clinical Practice Guideline J Clin Oncol 37 2270-2290

[3] Ruggiero SL(2022)American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update J Oral Maxillofac Surg 80 920-943

[4] Li J(2020)Positive effect of pentoxifylline on medication-related osteonecrosis of the jaw J Stomatol Oral Maxillofac Surg 121 264-267

[5] Wang W(2013)Effects of bisphosphonate treatment on DNA methylation in osteonecrosis of the jaw Mutat Res 757 104-113

[6] Polidoro S(2021)Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307) Support Care Cancer 29 2509-2517

[7] Kizub DA(2022)One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ) Support Care Cancer 30 7047-7051

[8] Fusco V(2022)Risk factors for developing medication-related osteonecrosis of the jaw when preserving the tooth that can be a source of infection in cancer patients receiving high-dose antiresorptive agents: a retrospective study Support Care Cancer 30 7241-7248

[9] Campisi G(2020)Bisphosphonates and risk of cancers: a systematic review and meta-analysis Br J Cancer 123 1570-1581

[10] Bedogni A(2008)Bisphosphonates: mechanism of action and role in clinical practice Mayo Clin Proc 83 1032-1045

[1] Ruggiero SL(2014)American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update J Oral Maxillofac Surg 72 1938-1956

[2] Yarom N(2019)Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO Clinical Practice Guideline J Clin Oncol 37 2270-2290

[3] Ruggiero SL(2022)American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update J Oral Maxillofac Surg 80 920-943

[4] Li J(2020)Positive effect of pentoxifylline on medication-related osteonecrosis of the jaw J Stomatol Oral Maxillofac Surg 121 264-267

[5] Wang W(2013)Effects of bisphosphonate treatment on DNA methylation in osteonecrosis of the jaw Mutat Res 757 104-113

[6] Polidoro S(2021)Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307) Support Care Cancer 29 2509-2517

[7] Kizub DA(2022)One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ) Support Care Cancer 30 7047-7051

[8] Fusco V(2022)Risk factors for developing medication-related osteonecrosis of the jaw when preserving the tooth that can be a source of infection in cancer patients receiving high-dose antiresorptive agents: a retrospective study Support Care Cancer 30 7241-7248

[9] Campisi G(2020)Bisphosphonates and risk of cancers: a systematic review and meta-analysis Br J Cancer 123 1570-1581

[10] Bedogni A(2008)Bisphosphonates: mechanism of action and role in clinical practice Mayo Clin Proc 83 1032-1045